Senti Biosciences, Inc.

Senti Biosciences, Inc. (SNTI) is a synthetic biology company that went public through a de-SPAC merger with Dynamics Special Purpose Corp, a blank-check vehicle that completed its IPO in 2021 and was co-sponsored by Casdin Capital and Viking Global Investors. The 10-Q/A filed December 10, 2021, under accession 0001193125-21-353987, is an amended quarterly report submitted during the pre-close period of the transaction. Senti operates in the life sciences and biotechnology sector, developing programmable gene circuit technologies for engineered cell therapies. The de-SPAC merger closed in June 2022, with the combined entity trading under the SNTI ticker. To access SpacDesk's full filing history, deal timelines, and SPAC analytics, sign up at SpacDesk.com.